<DOC>
	<DOCNO>NCT02768363</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness ProstAtak® immunotherapy patient undergo active surveillance localize prostate cancer . ProstAtak® involve use aglatimagene besadenovec ( AdV-tk ) kill tumor cell stimulate cancer vaccine effect . Killing tumor cell immune stimulatory environment induces body 's immune system detect destroy cancer cell . ProstAtak® well tolerate previous trial patient prostate cancer tumor type . Biochemical , pathologic immune response demonstrate newly diagnose recurrent prostate cancer . The hypothesis ProstAtak lead improvement clinical outcome patient prostate cancer . Participants randomize ProstAtak® control arm 2:1 ratio . Both arm receive standard care active surveillance evaluation .</brief_summary>
	<brief_title>Randomized Controlled Trial ProstAtak® Immunotherapy During Active Surveillance Prostate Cancer ( ULYSSES )</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Inclusion Criteria include : Histologically confirm adenocarcinoma prostate Patients choose active surveillance Patients meet definition NCCN low risk , intermediate risk OR patient one NCCN highrisk feature NCCN Low Risk define follow : PSA &lt; 10 ng/ml , Gleason ≤ 6 , T1T2a NCCN Intermediate Risk define least one follow high risk feature : PSA 1020 ng/ml , Gleason score =7 , T2bT2c High Risk single high risk feature define one following : PSA &gt; 20 ng/ml , Gleason score 810 , T3a Excluded follow risk group : High risk 1 high risk factor ; Locally advanced/very high risk=T3bT4 ; Metastatic : N1 M1 Patients must plan medically able tolerate multiple transrectal ultrasound guide injection . ECOG Performance status 02 Exclusion Criteria include : Active liver disease , include know cirrhosis active hepatitis Patients systemic corticosteroid ( &gt; 10 mg prednisone per day ) immunosuppressive drug Known HIV+ patient Regional lymph node involvement distant metastases Other current malignancy ( except squamous basal cell skin cancer ) Other serious comorbid illness compromise organ function , opinion investigator , would interfere treatment follow Prior treatment prostate cancer except TURP . If prior TURP , patient must deem able receive prostate biopsy multiple intraprostatic injection investigator Patients take 5alphareductase inhibitor ( e.g . finasteride , dutasteride ) Patients plan use ADT history orchiectomy . Patients plan undergo radical treatment prostate cancer within 12 month . Known sensitivity allergic reaction acyclovir valacyclovir</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Tumor vaccine</keyword>
	<keyword>Immuno-oncology</keyword>
	<keyword>Cytotoxicity</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>Active Surveillance</keyword>
</DOC>